TCM
CTMX icon

Tang Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Tang Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,065,662
Closed -$35.3M – 107
2025
Q3 		$35.3M Hold
11,065,662
– – 1.36% 21
2025
Q2 		$25.1M Buy
11,065,662
+4,347,837
+65% +$7.01M 1.27% 23
2025
Q1 		$4.27M Sell
6,717,825
-593,935
-8% -$461K 0.24% 78
2024
Q4 		$7.53M Sell
7,311,760
-500,000
-6% -$538K 0.5% 56
2024
Q3 		$9.22M Buy
7,811,760
+19,824
+0.3% +$25.2K 0.66% 45
2024
Q2 		$9.51M Buy
7,791,936
+1,341,936
+21% +$2.67M 0.97% 34
2024
Q1 		$14.1M Sell
6,450,000
-100,000
-2% -$185K 1.46% 22
2023
Q4 		$10.2M Buy
6,550,000
+100,000
+2% +$131K 0.94% 29
2023
Q3 		$8.32M Sell
6,450,000
-150,000
-2% -$236K 1.17% 28
2023
Q2 		$11.4M Buy
6,600,000
+506,968
+8% +$842K 1.67% 19
2023
Q1 		$9.2M Buy
6,093,032
+2,582,587
+74% +$5.84M 1.37% 27
2022
Q4 		$5.62M Buy
3,510,445
+10,445
+0.3% +$15.5K 0.82% 32
2022
Q3 		$5.08M Buy
3,500,000
+2,445,327
+232% +$3.76M 0.62% 42
2022
Q2 		$1.93M Buy
+1,054,673
New +$2.02M 0.29% 51
2022
Q1 		– Sell
-152,345
Closed -$660K – 54
2021
Q4 		$660K Buy
+152,345
New +$892K 0.13% 29
2020
Q4 		– Sell
-112,880
Closed -$751K – 13
2020
Q3 		$751K Sell
112,880
-187,120
-62% -$1.39M 0.14% 19
2020
Q2 		$2.5M Hold
300,000
– – 0.24% 17
2020
Q1 		$2.3M Buy
+300,000
New +$2.09M 0.32% 19

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Tang Capital Management's CTMX Position: Q4 2025 in Review

Tang Capital Management sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 11,065,662 shares — an estimated $35.3M sold.

Tang Capital Management first reported a position in CTMX in Q1 2020 and held it in 18 quarters. The position peaked at $35.3M in Q3 2025. 122 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Tang Capital Management reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 11,065,662 CytomX Therapeutics shares in Q4 2025, an estimated $35.3M.
  • Tang Capital Management first reported a position in CytomX Therapeutics in Q1 2020 and held it in 18 quarters.
  • Tang Capital Management's CytomX Therapeutics position peaked at $35.3M in Q3 2025.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.